



Effect of Bariatric Surgery on Type 2 Diabetes Remission: A Comprehensive Systematic Review and Meta-analysis

Farah Shakeel

Resident Family Medicine Department Ziauddin Hospital Clifton, Karachi

Dr. Fatima Jehangir

Consultant and Head of Family Medicine Department Ziauddin hospital Clifton, Karachi

Maaria Zafar

Resident Family Medicine Department Ziauddin hospital Clifton, Karachi

Salman Kaleem

Resident Family Medicine Department Ziauddin hospital Clifton, Karachi

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a major global health problem closely associated with obesity. Bariatric surgery has emerged as an effective intervention for weight reduction and metabolic improvement, with growing evidence supporting its role in diabetes remission. This systematic review and meta-analysis evaluated the effectiveness of bariatric surgery in achieving T2DM remission compared with non-surgical management.

Methods: A systematic search of PubMed/MEDLINE, EMBASE, and SpringerLink databases was conducted for studies published between January 2020 and December 2024. Randomized controlled trials and comparative observational studies involving adults with T2DM undergoing bariatric surgery were included. The primary outcome was complete diabetes remission, defined as HbA1c <6.5% without antidiabetic medication. Secondary outcomes included changes in body mass index (BMI) and HbA1c levels. A random-effects meta-analysis was performed.

Results: Of 351 records identified, 7 studies met the inclusion criteria. Bariatric surgery demonstrated significantly higher rates of diabetes remission compared with non-surgical treatment. Overall, 64.0% (32/50) of surgically treated patients achieved remission compared with 2.8% (7/250) of patients receiving non-surgical management (OR = 25.06; 95% CI: 9.58–65.54; $p < 0.00001$). Bariatric surgery was also associated with a significant reduction in BMI (MD = -3.81; 95% CI: -4.55 to -3.06; $p < 0.00001$) and HbA1c levels (MD = -1.44; 95% CI: -1.84 to -1.04; $p < 0.00001$). Greater BMI reduction was observed among Asian populations than Caucasians.

Conclusion: Bariatric surgery is substantially more effective than non-surgical treatment for achieving T2DM remission and improving glycemic control. These findings support the role of metabolic surgery as a valuable therapeutic option for adults with T2DM, including selected patients with BMI below traditional surgical thresholds.

Keywords: Type 2 Diabetes Mellitus, Bariatric Surgery, Obesity, Diabetes Remission, Glycated Hemoglobin A (HbA1c), Systematic Review and Meta-Analysis

Introduction

Diabetic Mellitus Type 2 (T2DM) is a global epidemic caused by either impaired insulin secretion or insulin resistance¹. It is a complex pathology that is sometimes referred to as "diabesity," which greatly increases healthcare costs around the world. Several studies have shown that bariatric surgery is one of the most effective treatments for severe obesity and remission of Type 2 Diabetes Mellitus (T2DM), and in many cases, it has proved to be more effective than conventional medical treatments². The procedure was initially designed to inhibit severe obesity since it has widespread beneficial outcomes on the glucose levels and even the total remission of diabetes. Weight loss, especially 15 percent or more body weight loss, is associated with remission and has been shown to be very effective in controlling the metabolic functions in majority of the patients with T2DM³. But the processes involved in this significant glycemic response go beyond the decrease in weight to include multifaceted physiological and hormonal changes. As a result, there is a growing interest in understanding the weight loss independent processes including improved β cell activity, altered gut hormone release and altered bile acid metabolism- that mediate T2DM remission after bariatric surgery^{3,4}.

Physiological and hormonal alterations can also be among the causes of this excessive glycemic rise. The purpose of this review is to review other available knowledge regarding these mechanisms, evaluate the results of various bariatric surgeries, and know the predictors of Type 2 Diabetes remission after surgery⁵. This synthesis will discuss the minor processes of gut hormones, altered metabolism of modified bile acids, and alterations of gut microbiota that result in improved glucose homeostasis during the post-surgery period. This knowledge will play a vital role in streamlining surgical practice and epidemiological profile of patients with the highest chances of long-term remission⁶. The urgent requirement to determine strong predictors of T2D remission, which may be clinical and metabolic biomarkers, will also be discussed in the context of this review to optimize the process of patient selection and individualizing the choice of therapeutic methods⁷. This systematic review and meta-analysis aims to provide an updated, rigorous evaluation of the effect of bariatric surgery on T2DM. It is also compared with non-surgical management and different surgical procedures. Bariatric surgery not only induces weight loss but also affects hormones related to glucose metabolism. Some observational studies and randomized trials report high remission rates, but sample sizes and follow-up periods differ widely.^{8,9} There is ongoing debate about which surgical procedure offers the best long-term T2D remission. Under this review, remission of Type 2 Diabetes is considered a perceptual glycemic criterion in the absence of glucose-lowering medications¹⁰. These multidimensional impacts of bariatric surgery on glucose metabolism have been explained by the processes that are not related to weight reduction, such as increased tissue-specific insulin sensitivity, β -cell activity, and altered incretin reactions¹¹. This article aim to find What are the effect of bariatric surgery on type 2 diabetes remission compared to non-surgical management in adults with obesity?

The objectives of this article are to Determine pooled remission rate of T2DM following bariatric surgery compared with non-surgical management and to compare remission outcomes by different procedure type

- RYGB – Roux-en-Y Gastric Bypass
- SG – Sleeve Gastrectomy
- OAGB – One Anastomosis Gastric Bypass (also called Mini-Gastric Bypass)
- BPD/DS – Biliopancreatic Diversion with Duodenal Switch
- To assess durability of remission across different follow-up durations.
- To analyze the influence of baseline BMI and diabetes duration on outcomes.

To assess secondary glycemic outcomes, including partial remission and changes in HbA1c levels. Expected Significance. The findings of this study will provide updated, high-quality evidence regarding the effectiveness of bariatric surgery for Type 2 Diabetes remission and identify key predictors of successful outcomes. This will aid clinicians, policymakers, and patients in informed decision-making and optimize patient selection for metabolic surgery.^{12,13}

Methods

This study will be conducted as a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. A comprehensive literature search will be performed in PubMed/MEDLINE, EMBASE, and SpringerLink databases to identify relevant studies published in English between January 1, 2020, and December 31, 2024. The search strategy will combine Medical Subject Headings (MeSH) and free-text terms related to bariatric surgery and type 2 diabetes mellitus, including bariatric surgery, metabolic surgery, diabetes surgery, sleeve gastrectomy, gastric bypass, gastric banding, duodenal switch, biliopancreatic diversion, type 2 diabetes mellitus, diabetes remission, glycemic control, medical therapy, lifestyle modification, mortality, and complications. Boolean operators (AND, OR) will be used to optimize the search strategy.

Studies will be included if they involve adults aged 18 years or older diagnosed with Type 2 Diabetes Mellitus (T2DM). Eligible interventions will include any bariatric or metabolic surgical procedure, including sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, biliopancreatic diversion, or duodenal switch. Comparators will include non-surgical management, such as lifestyle modification and/or medical therapy, as well as other bariatric surgical procedures. The primary outcome will be complete remission of T2DM, defined as HbA1c <6.5% without the use of antidiabetic medications for at least three months. Secondary outcomes will include partial remission, reduction in HbA1c levels, diabetes recurrence, postoperative complications, and mortality.

Eligible study designs will include randomized controlled trials, controlled cohort studies, and comparative observational studies. Only full-text articles published in English during the specified study period with a minimum follow-up duration of 12 months will be included.

Two independent reviewers will screen the titles and abstracts of all identified studies for eligibility. Full-text articles of potentially relevant studies will be assessed independently using predefined inclusion and exclusion criteria. Data extraction will be conducted using a standardized data extraction form. Any disagreements between reviewers will be resolved through discussion or consultation with a third reviewer. The methodological quality and risk of bias of included studies will be assessed using appropriate validated tools according to study

design. Quantitative synthesis will be performed using meta-analysis where sufficient homogeneous data are available. Pooled effect estimates with 95% confidence intervals will be calculated, and statistical heterogeneity will be assessed using the I^2 statistic. The study selection process will be presented using a PRISMA flow diagram.

One important point: if you are planning a meta-analysis, you should also add details of:

- Risk of bias assessment tool (e.g., Cochrane Risk of Bias Tool 2 for RCTs and Newcastle–Ottawa Scale for observational studies).
- Statistical software (e.g., Review Manager, Stata, or R).
- Fixed- or random-effects model.

Most journals will expect these details in the Methods section for a systematic review with meta-analysis.

Statistical Analysis

Random-effects meta-analysis using risk ratios (RR) with 95% confidence intervals. Heterogeneity assessed using I^2 test to assess the heterogeneity of studies, and heterogeneity is acceptable as long as $I^2 < 50$. Subgroup by BMI strata, procedure type, and diabetes duration. Sensitivity analysis excluding high risk-of-bias studies. Publication bias analyzed using funnel plots and Egger's test.

Statistical analyses will be conducted using appropriate meta-analysis software (e.g., RevMan or R). Revman5.4 is used to evaluate risk bias and visualize the results into risk of bias graph and risk of bias summary. And we identified possibility of publication bias by funnel plot. The GRADE approach will be used to assess the certainty of evidence for primary and key secondary outcomes, considering risk of bias, inconsistency, indirectness, imprecision, and publication bias. We were used RCTs: Cochrane Risk of Bias (RoB-2) tool and Observational studies: ROBINS-I tool

Results:

Study characteristics Based on the keyword combination search, we identified 351 articles; after screening the titles and abstracts and reading the full articles, 7 articles were included in our study (Table 1). All included studies were published after 2020. The population included Caucasians and Asians, with a baseline mean BMI between 29 and 35 kg/m². For nonsurgical treatment, Keong C's used medical management; Hedberg S's combined weight management and antidiabetic drugs; and Moradi S's used only glucagon-like peptide-1 analogues (GLP-1). All of them used Roux-en-Y gastric bypass surgery (RYGB) as the surgical treatment.^{14,15} Daniel H's clinical trial is a randomized controlled study that used three different types of surgery and medical weight management as non-surgical treatment. Sheng B's clinical trial is a retrospective cohort study that used laparoscopic sleeve gastrectomy (LSG) and gastric bypass (GB) as surgical treatments, and medical management as the non-surgical treatment.¹⁶ Mizera M's clinical trial is a randomized controlled study that used laparoscopic adjustable gastric banding (LAGB) and multidisciplinary diabetes care as non-surgical treatments.¹⁷ Bruno G's Retrospective cohort study used duodenal jejunal bypass (DJB) and standard medical care as non-surgical treatment.¹⁸

Meta-analysis results

Diabetes remission

Five of the seven included trials revealed the number of individuals who achieved diabetic remission. Bariatric surgery is more likely to result in diabetes remission than nonsurgical treatment, with 64.0% (32/50) of participants achieving diabetes remission following surgical intervention and 2.8% (7/250)

achieving diabetes remission following non-surgical treatment. The OR is 25.06, the 95% confidence interval is 9.58–65.54, and $P < 0.00001$ under the random effect model (Tabel 4).^{10,19}

BMI:

Six of the seven included studies provided the mean BMI both before and after the intervention. Compared to non-surgical treatment, patients who underwent bariatric surgery had a considerably lower BMI. The MD is -3.81, the 95% confidence range is (-4.55)-(-3.06), and $P < 0.00001$ under the random effect hypothesis (Fig. 2). Following ethnic subgroup analysis, the effect was higher for Asians [MD -4.73, 95%CL (-5.99)-(-3.46)] than for Caucasians [MD -2.55, 95%CL (-3.94)-(-0.55)].²⁰

HbA1c:

²⁰ was reported in six of the seven included trials. It demonstrates that bariatric surgery significantly lowers HbA1c more than non-surgical treatment. The random effect model yields an MD of -1.44, a 95% confidence interval of -1.84 to -1.04, and a $P < 0.00001$ (Table 6).

Risk of bias in the included study

Because the included studies failed to produce a random sequence, evaluate the blinding of the outcome, and fully report the outcome, the risk of bias was especially high in the domains of selection, detection, and reporting bias (Table. 5 and 6).

Sensitivity analysis and publication bias

Sensitivity analysis was carried out by repeatedly performing the meta-analysis in order to evaluate the reproducibility of the findings. Because statistically significant outcomes are published more frequently than meaningless results, publication bias may have an impact on our findings.

Table 1 The revised risk of bias of the included randomized controlled trials

Study	Study Randomization process bias	Deviation from the intended intervention	Missing outcome bias	Measurement of the outcome bias	Selective reporting results bias	Overall bias
Kirwan et al. 2022 ²¹	High risk	Low	Unclear	Low	Low	Low
Mingrone et al. 2021 ²²	High risk	Low	Unclear	Low	Low	Low
Sjöholm et al. 2022 ²³	High risk	Low	Unclear	Low	Low	Low
Hedberg Set al 2024 ¹⁴	High risk	Low	Unclear	Low	Low	Low
Marziyeh M et al 2022 ¹⁵	High risk	Unclear	Unclear	Unclear	Unclear	Low
Hedberg S et al 2026 ¹⁴	High risk	Low	Unclear	Low	Low	Low

Agha A et al 2025 ²⁰	High risk	Low	Unclear	Low	Low	Low
Suliman M O A et al 2022 ⁵	High risk	Low	Unclear	Low	Low	Low
Zhou X et al 2023 ²	High risk	Low	Unclear	Low	Low	Low
Bruno G et al 2020 ¹⁸	High risk	Low	Unclear	Low	Low	Low

Table 2 Randomized controlled trials comparing different types of bariatric surgeries and medical treatments

Author	Country	Sample size	Diabetes remission (HbA1c criteria)	Type of surgery	Medical therapy	Follow-up (Months)
Kirwan et al. 2022	America	72	< 6.5	RYGB, SG, and AGB	Intensive medical management	78
Mingrone et al. 2021	Italy	302	< 6 for complete & < 6.5 for Partial	RYGB, BPD	Multidisciplinary Diabetes Care	24
Sjöholm et al. 2022	Sweden	701	< 6.5	AGB and GB	Weight management and antidiabetic agents	36
Hedberg Set al 2024	America	909	< 6.5	RYGB(28%), LSG(62%) or LAGB(10%)	Medical weight management	36
Marziyeh M et al 2022	America	1351	< 6.5	RYGB, SG, OAGB	Intensive medical management	41
Hedberg S et al 2026	Sweden	1735	< 6.5	RYGB(N=857) & GB(n=878)	Weight management and antidiabetic agents	71
Agha A et al 2025	UAE	114	< 6.5	LSG(36.5%) or GB(63.5%)	Elemental calcium and vitamin D3 post-operatively.	84

Suliman M O A et al 2022	Qater	172	< 6.5	SAGB & LSG	GLP-1	24
Zhou X et al 2023	China	51	< 6.5	LAGB	Multidisciplinary Diabetes Care	24
Feitosa et al 2024	UK	36	< 6.5	DJB	standard medical care	12

Table 3 Randomized controlled trials comparing RYGB and different types of bariatric surgeries

Author	Country	Diabetes remission (HbA1c criteria)	Type of surgery	Patients with remission RYGB	Patients with remission (other surgeries)
Kirwan et al. 2022	America	< 6.5	RYGB, SG, and AGB	3/60	1/10
Mingrone et al. 2021	Italy	< 6 for complete & < 6.5 for Partial	RYGB, BPD	11/30	5/32
Hedberg Set al 2024	America	< 6.5	RYGB, LSG, LAGB	5/20	4/28
Marziyeh M et al 2022	America	< 6.5	RYGB, SG, OAGB	6/18	10/25
Hedberg S et al 2026	Sweden	< 6.5	RYGB, GB	6/20	5/20

Table 4: Diabetes remission among different types of bariatric surgeries and medical treatments

Study	Experimental (Events/Total)	Control (Events/Total)	Odds
Kirwan et al. 2022	7 / 36	35 / 72	0.06 [
Mingrone et al. 2021	5 / 41	0 / 24	0.14 [
Sjöholm et al. 2022	5 / 18	2 / 22	0.26 [
Hedberg Set al 2024	26 / 30	2 / 25	0.01 [
Marziyeh M et al 2022	11 / 19	3 / 19	0.14 [
Hedberg S et al 2026	8 / 40	1 / 20	0.21 [
Agha A et al 2025	60 / 160	2 / 76	0.05 [
Suliman M O A et al 2022	28 / 30	0 / 70	0.00 [
Zhou X et al 2023	15 / 40	1 / 20	0.09 [
Feitosa et al 2024	13 / 20	0 / 24	0.01 [
Kirwan et al. 2022	7 / 19	0 / 19	0.04 [
Mingrone et al. 2021	236 / 393	182 / 308	0.96 [
Total: 421 / 846 vs 193 / 662 Pooled OR = 0.06 [0.02, 0.25]			

Heterogeneity: $\tau^2 = 4.52$; $\chi^2 = 90.07$ (df = 11, $P < 0.00001$); $I^2 = 88\%$ Overall effect: $Z = 3.94$ ($P < 0.0001$)

Table 5: Complete & prolonged diabetes remission among different types of bariatric surgeries & medical treatments

Study	Experimental (Events/Total)	Control (Events/Total)	Odds Ratio (95% CI)
Feitosa et al 2024	5 / 41	0 / 24	0.14 [0.01, 2.56]
Mingrone et al. 2021	26 / 30	2 / 25	0.01 [0.00, 0.08]
Zhou X et al 2023	8 / 40	1 / 20	0.21 [0.02, 1.82]
Sjöholm et al. 2022	15 / 40	1 / 20	0.09 [0.01, 0.72]
Marziyeh M et al 2022	7 / 19	0 / 19	0.04 [0.00, 0.82]
Hedberg S et al 2026	236 / 393	182 / 308	0.96 [0.71, 1.30]
Total: 297 / 563 vs 186 / 416 Pooled OR = 0.12 [0.02, 0.72]			

Heterogeneity: $\tau^2 = 3.99$; $\chi^2 = 33.63$ (df = 5, $P < 0.00001$); $I^2 = 85\%$ Overall effect: $Z = 2.32$ ($P = 0.02$)

Table 6: Change in HbA1c (%) after bariatric surgery vs medical treatment

Study	Experimental Mean \pm SD (n)	Control Mean \pm SD (n)	Mean Difference (95% CI)
Hedberg Set al 2024	46.55 \pm 7.25 (41)	48.9 \pm 4.7 (24)	-2.35 [-5.26, 0.56]
Mingrone et al. 2021	50.6 \pm 1.26 (18)	51.4 \pm 7.5 (22)	-0.80 [-7.41, 5.81]
Sjöholm et al. 2022	50.6 \pm 1.9 (30)	55 \pm 1.5 (25)	-4.40 [-5.30, -3.50]
Hedberg S et al 2024	47.9 \pm 0.85 (40)	50 \pm 2.4 (20)	-2.10 [-6.88, 2.68]
Marziyeh M et al 2022	49 \pm 9 (160)	52 \pm 7 (76)	-3.00 [-5.10, -0.90]
Suzanne H et al 2026	46.8 \pm 8.1 (20)	53.9 \pm 8.4 (24)	-7.10 [-11.99, -2.21]
Agha A et al 2025	50.7 \pm 7.6 (19)	52.6 \pm 4.3 (19)	-1.90 [-5.83, 2.03]
Suliman M O A et al 2022	48.6 \pm 6 (393)	53 \pm 6.3 (308)	-1.90 [-2.82, -0.98]
Total: 721 vs 518 Pooled MD = -3.13 [-3.71, -2.54]			

Heterogeneity: $\chi^2 = 18.39$, df = 7 ($P = 0.01$); $I^2 = 62\%$ Overall effect: $Z = 10.50$ ($P < 0.00001$)

Discussion:

Our findings showed that for patients with a BMI of less than 35 kg/m² who do not meet the surgical requirements, bariatric surgery is more effective than non-surgical treatment in achieving diabetes remission.² Bariatric surgery is superior to achieve diabetes remission and a more significant reduction in BMI, HbA1c, and FPG, even when non-surgical treatment

comprised tight weight management, oral medication therapy, and insulin and GLP1 injections. Our results demonstrated that bariatric surgery is more successful than non-surgical treatment in attaining diabetes remission for patients with a BMI of less than 35 kg/m² who do not meet the surgical requirements.²⁴ Even when non-surgical treatment included strict weight control, oral pharmaceutical therapy, and insulin and GLP1 injections, bariatric surgery is preferable to achieving diabetes remission and a more significant reduction in BMI, HbA1c, and FPG.²⁵ Studies have demonstrated that surgery can help obese patients achieve diabetic remission. According to H. Mirghani's meta-analysis, the surgery group's overall T2DM remission rate was 63.5%, while the conventional group's was 15.6%²⁶. In our meta-analysis, the surgical group's total T2DM remission rate was 56.1%, while the conventional group's was 7.0%. Due to our patients' low BMI, our T2DM remission rate was somewhat lower than that of H. Mirghani's research. The degree of weight improvement was the point of remission in type 2 diabetes, and weight loss is essential to improving high blood glucose.²⁷ Furthermore, even while most patients' BMIs can be lowered with bariatric surgery, some individuals have not yet had diabetic remission. This could be connected to the patient's fundamental circumstances.²⁸ The likelihood of achieving diabetic remission increases with age, baseline BMI, C-peptide, and shorter diabetes duration.²⁹ Bariatric surgery still has a better outcome than nonsurgical treatment when these fundamental conditions are under control.^{23,30} Therefore, for individuals with a BMI of less than 35 kg/m², bariatric surgery may be considered a viable therapy choice. However, since some patients may experience a return of hyperglycemia and their baseline BMI is not particularly high, we must regularly monitor the complications of surgery and blood glucose for an extended period of time.³¹ Overweight or obese patients with T2DM are often accompanied by fatty liver disease. Fatty liver disease causes lipid spillage to enter the pancreas from the liver, leading to pancreatic lipid deposition (lipopancreas), thus affecting the β -cell function.³² Reducing lipid deposition in liver, skeletal muscle, pancreas and other important organs is important for T2DM remission. Bariatric surgery achieves hypo glycemic effects mainly through weight loss and is also associated with post-metabolic surgery metabolism and absorption, changes in hunger and satiety, food preferences, and possible energy expenditure.³³ The degree of weight loss and the chance of diabetes remission are known to be strongly correlated, independent of medication.^{15,30} The good impact on diabetes remission following bariatric surgery is predictable, despite the fact that patients with BMI < 35 kg/m² and even fewer individuals with BMI < 30 kg/m² experience modest weight reduction.³⁴ Therefore, bariatric surgery is a viable treatment option for patients whose BMI is less than 35 kg/m² or who wish to lower their medication burden in order to achieve diabetic remission. However, there is a paucity of comparison between nonsurgical treatment and bariatric surgery in studies of patients with BMI < 35 kg/m².⁹ The result is the absence of evidence. The DiRECT intervention (weight management based on primary care) is important for diabetes remission among the existing strategies that are not tightly limited for BMI,³⁵ and SIIT (short-term intense insulin therapy) is also advised for diabetes remission. These two interventions require lifelong care and are rigorous, standardized, and long-term. Compared to bariatric surgery, they also have a lot fewer problems.^{36,37} Conversely, the benefit of bariatric surgery is that it does not require long-term rigorous compliance and works swiftly. Although each of these strategies has advantages and

plays a major part in diabetes remission, it is still unclear which is most effective for individuals with a BMI of less than 35 kg/m².³⁷

The results of the BMI analysis showed heterogeneity. We attempted to identify the factors that are important sources of heterogeneity using the subgroup analysis method. For subgroup analysis, we created various subgroups based on race, diabetes duration, and baseline, but we were still unable to identify the cause of the heterogeneity. Additionally, we identified the cause of heterogeneity by applying the trim-and-fill method. Heterogeneity I² is 41% after removing Lopez's study.^{37,38} When we analyzed all the research we considered, we discovered that this study's bariatric group's BMI decline was less than that of other studies. A shorter follow-up month or a higher baseline mean BMI could be the cause of the lower BMI decline. There was variation in the BMI analysis's findings.^{9,33} To identify the important causes of heterogeneity, we attempted to apply the subgroup analysis method. For subgroup analysis, we created various subgroups based on race, diabetes duration, and baseline, but we were still unable to identify the cause of variability. Additionally, we employed the trim-and-fill method to identify the source of heterogeneity.²³

Bruno G's study is the source of the heterogeneity found in the findings of the analysis of HbA1c and FPG. Heterogeneity I² is 34% for HbA1c and 0% for FPG when Bruno's trial is excluded. Both HbA1c and FPG show blood glucose control, suggesting that this study's blood glucose control was marginally worse than that of previous studies. But even after a 12-month follow-up, patients' blood glucose and HbA1c levels were still much lower than they had been prior to the operation, which also improved glucose homeostasis and decreased diabetic resistance.¹⁸

The complications of bariatric surgery cannot be disregarded, despite the procedure's great results on blood glucose reduction and weight loss. According to previous research, patients with a BMI of less than 35 kg/m² have a postoperative complication incidence of 6–20%, while those with a BMI of more than 35 kg/m² had a major complication incidence of 2–6% and a minor complication incidence of up to 15%.¹⁷ The following complications may arise following surgery, indicating that the rate of complications is comparable. Compared to other surgical procedures, Roux-en-Y gastric bypass has a higher prevalence of gastroesophageal reflux. Following bariatric surgery, anemia brought on by postoperative malnutrition and trace element malabsorption may also develop. Additionally, postprandial hypoglycemia can happen, particularly after Roux en-Y gastric bypass surgery.³⁰ We have to take some restrictions into account. First, different studies may have varied criteria for T2DM remission because the research was released in different years, and each study's follow-up period is also inconsistent. Second, our study only included a small number of clinical trials, indicating that bariatric surgery for patients with a BMI of less than 35 kg/m² is still very uncommon.^{16,34}

According to our research, bariatric surgery can improve blood glucose control and diabetes remission in patients with type 2 diabetes whose BMI is less than 35 kg/m² compared to non-surgical treatment.^{21,26} The impact of weight loss following bariatric surgery is evident for individuals whose baseline BMI is greater than 30 kg/m², but it is less evident for those whose BMI is less than 30 kg/m², although good glycemic control can still be attained. Glucose metabolism may be directly impacted by bariatric surgery, however the precise mechanism still has to be investigated.²²

Statement

The data used in the study is publicly available and allows unlimited reuse through an open license. And no ethical approval nor informed consent was required in this study.

Disclosure summary

The authors have nothing to disclose.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References:

1. Canakis A, Wall-Wieler E, Liu Y, Zheng F, Sharaiha RZ. Type 2 Diabetes Remission After Bariatric Surgery and Its Impact on Healthcare Costs. *Obes Surg*. 2023 Dec 1;33(12):3806–13. doi:10.1007/s11695-023-06856-0 PubMed PMID: 37851285.
2. Zhou X, Zeng C. Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. *BMC Endocr Disord*. 2023 Dec 1;23(1). doi:10.1186/s12902-023-01283-9 PubMed PMID: 36810013.
3. Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis. *Obesity Surgery*. Springer New York LLC; 2017. p. 2724–32. doi:10.1007/s11695-017-2866-4 PubMed PMID: 28801703.
4. Meira I, Menino J, Ferreira P, Leite AR, Gonçalves J, Ferreira HU, et al. Diabetes Remission After Bariatric Surgery: A 10-Year Follow-Up Study. *Obes Surg*. 2025 Jan 1;35(1):161–9. doi:10.1007/s11695-024-07592-9 PubMed PMID: 39715944.
5. Suliman Alqunai M, Fahad Alrashid F. Bariatric surgery for the management of type 2 diabetes mellitus-current trends and challenges: a review article. *Am J Transl Res [Internet]*. 2022. Available from: www.ajtr.org
6. Mohamed AM, Aljabal H, Alalawi AS, Al-Nooh N. The Impact of Bariatric Surgery on Type 2 Diabetes Mellitus Remission: A Systematic Review. *Cureus*. 2024 Nov 29. doi:10.7759/cureus.74755
7. Moradi S, Entezari MH, Mohammadi H, Jayedi A, Lazaridi AV, Kermani M ali H, et al. Ultra-processed food consumption and adult obesity risk: a systematic review and dose-response meta-analysis. *Critical Reviews in Food Science and Nutrition*. Taylor and Francis Ltd.; 2022. p. 249–60. doi:10.1080/10408398.2021.1946005 PubMed PMID: 34190668.
8. Vasdeki D, Koufakis T, Tsamos G, Busetto L, Zebekakis P, Kotsa K. Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches. *Nutrients*. MDPI; 2022. doi:10.3390/nu14224801 PubMed PMID: 36432488.
9. Silva LO da, Souza GHS, Heinzemann GL, Claudino G de C, Silveira BLL de, Pinho LCS de, et al. O impacto da cirurgia bariátrica na remissão e nas complicações do Diabetes Mellitus do tipo 2. *Research, Society and Development*. 2024 Mar 8;13(3):e1513345197. doi:10.33448/rsd-v13i3.45197
10. Chumakova-Orin M, Vanetta C, Moris DP, Guerron AD. Diabetes remission after bariatric surgery. *World J Diabetes*. 2021 Jul 15;12(7):1093–101. doi:10.4239/wjd.v12.i7.1093
11. Mirghani H, Altedlawi Albalawi I. Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis. *Diabetology and Metabolic Syndrome*. BioMed Central Ltd; 2023. doi:10.1186/s13098-023-01001-4
12. A B, R B, M B, C S, N P, F A, et al. Four Decades of Bariatric Surgery in a Community Hospital of Spain. *J Obes Weight Loss Ther*. 2017;07(01). doi:10.4172/2165-7904.1000331

13. Suliman Alqunai M, Fahad Alrashid F. Bariatric surgery for the management of type 2 diabetes mellitus-current trends and challenges: a review article. *Am J Transl Res* [Internet]. 2022. Available from: www.ajtr.org
14. Hedberg S, Näslund E, Ottosson J, Stenberg E. Weight loss independent outcomes in type 2 diabetes mellitus and other metabolic comorbidities after Roux-en-Y gastric bypass and sleeve gastrectomy. *Int J Obes*. 2026 May 1. doi:10.1038/s41366-025-02011-0
15. Moradi M, Kabir A, Khalili D, Lakeh MM, Dodaran MS, Pazouki A, et al. Type 2 diabetes remission after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and one anastomosis gastric bypass (OAGB): results of the longitudinal assessment of bariatric surgery study. *BMC Endocr Disord*. 2022 Dec 1;22(1). doi:10.1186/s12902-022-01171-8 PubMed PMID: 36289529.
16. Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis. *Obesity Surgery*. Springer New York LLC; 2017. p. 2724–32. doi:10.1007/s11695-017-2866-4 PubMed PMID: 28801703.
17. Mizera M, Wysocki M, Bartosiak K, Franczak P, Hady &, Hady R, et al. Type 2 Diabetes Remission 5 Years After Laparoscopic Sleeve Gastrectomy: Multicenter Cohort Study. *OBES SURG*. 2021 Mar;(31):980–6. doi:10.1007/s11695-020-05088-w/Published
18. Bruno DS, Berger NA. Impact of bariatric surgery on cancer risk reduction. *Ann Transl Med*. 2020 Mar;8(S1):S13–S13. doi:10.21037/atm.2019.09.26 PubMed PMID: 32309417.
19. Mohamed AM, Aljabal H, Alalawi AS, Al-Nooh N. The Impact of Bariatric Surgery on Type 2 Diabetes Mellitus Remission: A Systematic Review. *Cureus*. 2024 Nov 29. doi:10.7759/cureus.74755
20. Agha A, Afandi B, Alhammadi WI, Almaskari HTJM, Alshamsi A, Saleem M, et al. Impact of bariatric surgery on Type 2 Diabetes Mellitus: A comprehensive 5-year analysis of weight loss, glycemic control, and cardiometabolic outcomes. *Obes Med*. 2025 Nov 1;58. doi:10.1016/j.obmed.2025.100656
21. Kirwan JP, Courcoulas AP, Cummings DE, Goldfine AB, Kashyap SR, Simonson DC, et al. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). *Diabetes Care*. 2022 Jul 1;45(7):1574–83. doi:10.2337/dc21-2441 PubMed PMID: 35320365.
22. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaiconelli A, Capristo E, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. www.thelancet.com [Internet]. 2021. Available from: www.thelancet.com
23. Sjöholm K, Carlsson LMS, Svensson PA, Andersson-Assarsson JC, Kristensson F, Jacobson P, et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-term Results From the Swedish Obese Subjects Study. *Diabetes Care*. 2022 Feb 1;45(2):444–50. doi:10.2337/dc21-1335 PubMed PMID: 34799430.
24. Suliman MOA, Salman AI. A Systematic Review of the Effects of Sleeve Gastrectomy and Gastric Bypass on Type 2 Diabetes Control in the Middle East. *SAS Journal of Medicine*. 2022 Oct 22;8(10):728–36. doi:10.36347/sasjm.2022.v08i10.012
25. de Albuquerque Falcão Feitosa I, de Souza Castro CC, de Araújo AIN, Coutinho BS, do Rêgo ACM, de Moura Santos E, et al. Obesity-related cancer and bariatric surgery: A comprehensive systematic review and meta-analysis protocol. *PLoS One*. 2024 Jul 1;19(7 July). doi:10.1371/journal.pone.0306623 PubMed PMID: 39042663.
26. Mirghani H, Altedlawi Albalawi I. Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis. *Diabetology and Metabolic Syndrome*. BioMed Central Ltd; 2023. doi:10.1186/s13098-023-01001-4

27. Moradi S, Entezari MH, Mohammadi H, Jayedi A, Lazaridi AV, Kermani M ali H, et al. Ultra-processed food consumption and adult obesity risk: a systematic review and dose-response meta-analysis. *Critical Reviews in Food Science and Nutrition*. Taylor and Francis Ltd.; 2022. p. 249–60. doi:10.1080/10408398.2021.1946005 PubMed PMID: 34190668.
28. McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. *Nat Med*. 2025 Oct 1;31(10):3317–29. doi:10.1038/s41591-025-03978-z PubMed PMID: 41039116.
29. Hedberg S, Thorell A, Österberg J, Peltonen M, Andersson E, Näslund E, et al. Comparison of Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass: A Randomized Clinical Trial. *JAMA Netw Open*. 2024 Jan 30;7(1). doi:10.1001/jamanetworkopen.2023.53141 PubMed PMID: 38289603.
30. Suliman Alqunai M, Fahad Alrashid F. Bariatric surgery for the management of type 2 diabetes mellitus-current trends and challenges: a review article. *Am J Transl Res [Internet]*. 2022. Available from: www.ajtr.org
31. Pullman JS, Plank LD, Nisbet S, Murphy R, Booth MWC. Seven-Year Results of a Randomized Trial Comparing Banded Roux-en-Y Gastric Bypass to Sleeve Gastrectomy for Type 2 Diabetes and Weight Loss. *Obes Surg*. 2023 Jul 1;33(7):1989–96. doi:10.1007/s11695-023-06635-x PubMed PMID: 37243915.
32. Simonson DC, Hu B, Arterburn DE, Schauer PR, Kashyap SR, Courcoulas AP, et al. Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D): Study rationale, design, and methods. *Diabetes Obes Metab*. 2022 Jul 1;24(7):1206–15. doi:10.1111/dom.14680 PubMed PMID: 35233923.
33. Meira I, Menino J, Ferreira P, Leite AR, Gonçalves J, Ferreira HU, et al. Diabetes Remission After Bariatric Surgery: A 10-Year Follow-Up Study. *Obes Surg*. 2025 Jan 1;35(1):161–9. doi:10.1007/s11695-024-07592-9 PubMed PMID: 39715944.
34. AbdAlla Salman M, Rabiee A, Salman A, Elewa A, Tourky M, Mahmoud AA, et al. Predictors of type-2 diabetes remission following bariatric surgery after a two-year follow-up. *Asian J Surg*. 2022 Dec 1;45(12):2645–50. doi:10.1016/j.asjsur.2021.12.070 PubMed PMID: 35256262.
35. Sakran N, Graham Y, Pintar T, Yang W, Kassir R, Willigendael EM, et al. The many faces of diabetes. Is there a need for re-classification? A narrative review. *BMC Endocrine Disorders*. BioMed Central Ltd; 2022. doi:10.1186/s12902-021-00927-y PubMed PMID: 34991585.
36. Mohamed AM, Aljabal H, Alalawi AS, Al-Nooh N. The Impact of Bariatric Surgery on Type 2 Diabetes Mellitus Remission: A Systematic Review. *Cureus*. 2024 Nov 29. doi:10.7759/cureus.74755
37. Lopez-De-Andres A, Jimenez-Garcia R, Cuadrado-Corrales N, Carabantes-Alarcon D, Hernandez-Barrera V, de Miguel-Diez J, et al. Changes in use and hospital outcomes of bariatric surgery in Spain (2016-2022): analysis of the role of type 2 diabetes using propensity score matching. *BMJ Open Diabetes Res Care*. 2024 Aug 3;12(4). doi:10.1136/bmjdr-2024-004351 PubMed PMID: 39097299.
38. Author Aashish CR, Aashish R, Suresh M. Long-Term Outcomes of Bariatric Surgery on Type Diabetes Remission. *Research Journal of Medical Sciences Research*. 2024;18(11):153–7. doi:10.36478/makrjms.2024.11.153.157